Health care stocks were flat to higher pre-bell Tuesday as the iShares Biotechnology ETF (IBB) was flat and the Health Care Select Sector SPDR Fund (XLV) was up 0.2%.
Sangamo Therapeutics (SGMO) shares fell past 52% after the company said it will regain full development and commercialization rights for giroctocogene fitelparvovec as Pfizer (PFE) decided to terminate the collaboration and licensing agreement for the prospective hemophilia A gene therapy.
Corcept Therapeutics (CORT) shares rose by more than 5% after the company said it filed a new drug application to the US Food and Drug Administration for relacorilant to treat patients with endogenous hypercortisolism.
Acadia Pharmaceuticals (ACAD) is set to join the S&P SmallCap 600 index on Jan. 3, replacing Independent Bank Group (IBTX), S&P Dow Jones Indices said. Acadia Pharmaceuticals shares were up over 8% premarket.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。